AGP Executive Report
Last update: 8 hours agoCBD for pain: A University of Sydney randomized trial reports CBD inhalation cut chronic neuropathic pain about 14% over six weeks (vs 6.5% placebo), with some people seeing 30%+ relief. Neuroinflammation angle: Another new study says CBD may slow Alzheimer’s by calming brain immune inflammation in an Alzheimer’s mouse model. Arthritis capsules: A separate patient study found cannabinoid capsules (including CBD/CBDa and THC combos) reduced chronic arthritis pain across fibromyalgia, rheumatoid arthritis, and osteoarthritis groups. Cannabis policy in Minnesota: Gov. Tim Walz signed a sweeping 2026 cannabis omnibus bill, including merging medical and adult-use supply chains and creating new licensing rules. Legal fight over hemp THC: Indiana AG Todd Rokita joins a lawsuit to block the federal shift that would move marijuana from Schedule I to Schedule III. Mainstreaming trend: Coverage highlights how cannabis is moving from counterculture into everyday wellness talk—sleep, stress, and routines—while still raising questions about responsible use. Vermont pesticide ban: Vermont becomes the first state to ban paraquat over possible links to Parkinson’s and organ damage. Industry/legal pressure: Victoria’s Sexual Health Victoria says it’s closing a Melbourne clinic despite rising STI demand. Recall alert: FDA recalls “Boner Bears Sex Chocolate” for undeclared sildenafil (Viagra), warning of dangerous interactions for some people. Spending spotlight: Nigerian rapper Ice Prince says he spent ₦340m on weed over six years, as he discusses quitting smoking for weight loss.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
